CN101505785A - 替奈普酶用于治疗急性缺血性中风的用途 - Google Patents

替奈普酶用于治疗急性缺血性中风的用途 Download PDF

Info

Publication number
CN101505785A
CN101505785A CNA2007800318116A CN200780031811A CN101505785A CN 101505785 A CN101505785 A CN 101505785A CN A2007800318116 A CNA2007800318116 A CN A2007800318116A CN 200780031811 A CN200780031811 A CN 200780031811A CN 101505785 A CN101505785 A CN 101505785A
Authority
CN
China
Prior art keywords
tenecteplase
dose
administered
bolus
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800318116A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·库布勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101505785(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN101505785A publication Critical patent/CN101505785A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CNA2007800318116A 2006-08-29 2007-08-01 替奈普酶用于治疗急性缺血性中风的用途 Pending CN101505785A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82386806P 2006-08-29 2006-08-29
US60/823,868 2006-08-29

Publications (1)

Publication Number Publication Date
CN101505785A true CN101505785A (zh) 2009-08-12

Family

ID=38835003

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800318116A Pending CN101505785A (zh) 2006-08-29 2007-08-01 替奈普酶用于治疗急性缺血性中风的用途

Country Status (21)

Country Link
US (2) US20080107641A1 (https=)
EP (1) EP2056856B1 (https=)
JP (1) JP5785687B2 (https=)
KR (1) KR20090045405A (https=)
CN (1) CN101505785A (https=)
AU (1) AU2007290277B2 (https=)
BR (1) BRPI0716143A2 (https=)
CA (1) CA2661012C (https=)
CO (1) CO6150188A2 (https=)
EA (1) EA015573B1 (https=)
EC (1) ECSP099178A (https=)
IL (2) IL196987A (https=)
MX (1) MX2009001918A (https=)
MY (1) MY163119A (https=)
NO (1) NO342302B1 (https=)
NZ (1) NZ574767A (https=)
SG (3) SG10201804944XA (https=)
TW (1) TWI439282B (https=)
UA (1) UA97486C2 (https=)
WO (1) WO2008027687A2 (https=)
ZA (1) ZA200900957B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103391785A (zh) * 2010-12-23 2013-11-13 热诺瓦生物制药有限公司 替萘普酶的药用组合物
CN110214015A (zh) * 2017-01-24 2019-09-06 Ekos公司 用于治疗血栓栓塞的方法
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用
CN115487294A (zh) * 2022-07-12 2022-12-20 上海丰华天力通生物医药有限公司 替奈普酶在制备用于治疗轻型缺血性卒中的药物组合物中的应用
CN115551531A (zh) * 2020-02-19 2022-12-30 诺诺公司 纤溶酶可裂解的psd-95抑制剂与再灌注联合治疗中风

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
UA97486C2 (ru) 2006-08-29 2012-02-27 Дженентек, Инк. Применение тенектеплазы для лечения острого ишемического инсульта
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
US9034007B2 (en) 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal embolic protection devices with a variable thickness microguidewire and methods for their use
EP2384141A1 (en) * 2008-12-24 2011-11-09 Koninklijke Philips Electronics N.V. System, method and apparatus for cardiac intervention with mr stroke detection and treatment
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
CA2772097C (en) 2009-08-24 2019-04-30 Hough Ear Institute Methods for treating acute acoustic trauma
KR101891357B1 (ko) 2010-06-02 2018-08-24 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 경구용 제형
US20150238502A1 (en) * 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
US8690907B1 (en) 2013-03-15 2014-04-08 Insera Therapeutics, Inc. Vascular treatment methods
US8679150B1 (en) 2013-03-15 2014-03-25 Insera Therapeutics, Inc. Shape-set textile structure based mechanical thrombectomy methods
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
CN116172656A (zh) 2013-03-15 2023-05-30 伊瑟拉医疗公司 脉管治疗装置和方法
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
PT3209767T (pt) * 2014-10-21 2020-11-09 Gennova Biopharmaceuticals Ltd Um novo processo de purificação para isolamento e produção comercial de tnk-tpa recombinante (tenecteplase)
EP3416568A4 (en) 2016-02-16 2019-10-16 Insera Therapeutics, Inc. SUCTION DEVICES AND ANCHORED FLOW REVERSING DEVICES
US11185523B2 (en) 2016-03-24 2021-11-30 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
WO2018210860A1 (en) * 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
US20230068460A1 (en) * 2020-02-04 2023-03-02 The Regents Of The University Of Colorado, A Body Corporate Prophylactic uses of annexin a2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DK0643772T3 (da) 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
JP2002173447A (ja) * 2000-09-29 2002-06-21 Yamanouchi Pharmaceut Co Ltd 脳塞栓症治療用医薬組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
UA97486C2 (ru) 2006-08-29 2012-02-27 Дженентек, Инк. Применение тенектеплазы для лечения острого ишемического инсульта

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103391785A (zh) * 2010-12-23 2013-11-13 热诺瓦生物制药有限公司 替萘普酶的药用组合物
CN110214015A (zh) * 2017-01-24 2019-09-06 Ekos公司 用于治疗血栓栓塞的方法
CN115551531A (zh) * 2020-02-19 2022-12-30 诺诺公司 纤溶酶可裂解的psd-95抑制剂与再灌注联合治疗中风
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用
CN115487294A (zh) * 2022-07-12 2022-12-20 上海丰华天力通生物医药有限公司 替奈普酶在制备用于治疗轻型缺血性卒中的药物组合物中的应用

Also Published As

Publication number Publication date
SG10201501498VA (en) 2015-04-29
HK1131054A1 (en) 2010-01-15
CO6150188A2 (es) 2010-04-20
NZ574767A (en) 2012-02-24
CA2661012C (en) 2019-03-19
UA97486C2 (ru) 2012-02-27
NO342302B1 (no) 2018-04-30
US20080107641A1 (en) 2008-05-08
TW200817033A (en) 2008-04-16
AU2007290277A1 (en) 2008-03-06
CA2661012A1 (en) 2008-03-06
JP5785687B2 (ja) 2015-09-30
WO2008027687A2 (en) 2008-03-06
BRPI0716143A2 (pt) 2013-11-26
MY163119A (en) 2017-08-15
WO2008027687A3 (en) 2008-05-22
MX2009001918A (es) 2009-03-06
EA015573B1 (ru) 2011-10-31
IL248176A0 (en) 2016-11-30
US9023346B2 (en) 2015-05-05
AU2007290277B2 (en) 2013-04-11
SG174753A1 (en) 2011-10-28
NO20091296L (no) 2009-05-28
TWI439282B (zh) 2014-06-01
EP2056856A2 (en) 2009-05-13
ZA200900957B (en) 2010-05-26
KR20090045405A (ko) 2009-05-07
EP2056856B1 (en) 2015-01-14
SG10201804944XA (en) 2018-07-30
EA200970237A1 (ru) 2009-08-28
IL196987A0 (en) 2011-08-01
JP2010502629A (ja) 2010-01-28
US20120164157A1 (en) 2012-06-28
ECSP099178A (es) 2009-06-30
IL196987A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
AU2007290277B2 (en) Use of tenecteplase for treating acute ischemic stroke
Barreto Intravenous thrombolytics for ischemic stroke
EP3395359B1 (en) Plasminogen for use in preventing or treating acute thrombosis and chronic thrombosis
RU2166326C2 (ru) Комбинация тромболитически активных белков и антикоагулянтов
EP4112069B1 (en) Components of the plasminogen activation pathway for use in the treatment of hypertension
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
HK1131054B (en) Use of tenecteplase for treating acute ischemic stroke
Clark et al. Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents
Weiner Thrombolytic agents in critical care
Larrue Intravenous alteplase for acute ischaemic stroke
HK40084753B (en) Components of the plasminogen activation pathway for use in the treatment of hypertension
Walsh Tissue Plasminogen Activator-Based Thrombolytic Agents
JP2022551373A (ja) 三環式誘導体を用いた脳卒中の治療方法
FAST What happens during a stroke
Diaz-Ricart Desmoteplase
EP2289541A1 (en) Treatment of neurological or neurodegenerative disorders
JP2008507561A (ja) 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
WO2007134813A2 (en) Use of desmodus salivary plasminogen activator (dspa) for treating venous thromboembolism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090812